Adrienne Burford Foggs
Rheumatology · Chicago, ILNPI 1619921541
Payments from drug & device makers
Across 205 payments — averaging $26.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Johnson & Johnson$1K
- AstraZeneca$579
- GSK$530
- Pfizer$438
- AbbVie$428
- plus $1K from 14 others
What the payments were for
- Consulting fees$75014%
- Grants$2404%
- Food & beverage$4,36979%
- Education$1463%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 72 | $1,350 |
| Johnson & Johnson(3 entities) | 10 | $1,039 |
| AstraZeneca | 24 | $579 |
| GSK | 21 | $530 |
| Pfizer | 18 | $438 |
| AbbVie(2 entities) | 13 | $428 |
| E.r. Squibb & Sons, L.L.C. | 14 | $314 |
| Mallinckrodt Hospital Products Inc. | 9 | $306 |
| Arbor Pharmaceuticals, Inc. | 6 | $99 |
| Lilly USA, LLC | 3 | $72 |
| Radius Health, Inc. | 3 | $56 |
| Sanofi | 3 | $55 |
| Mallinckrodt Enterprises LLC | 2 | $53 |
| Octapharma USA, Inc. | 1 | $43 |
| Fresenius Kabi USA, LLC | 1 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Hikma Pharmaceuticals USA | 1 | $25 |
| Genentech USA, Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,504 in reported general payments places this provider in the 70th percentile of 287 rheumatology providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 27 | $197,578 |
| LinzessLinaclotide | 25 | $23,971 |
| OzempicSemaglutide | 20 | $19,193 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $4,855 |
| EdarbiAzilsartan Medoxomil | 13 | $4,673 |
| Hydroxychloroquine Sulfate | 38 | $1,172 |
| Gabapentin | 41 | $1,109 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $829 |
| Nifedipine ErNifedipine | 26 | $775 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $739 |
| Pregabalin | 13 | $734 |
| Potassium Chloride | 31 | $690 |
| Azelastine Hcl | 11 | $652 |
| Atorvastatin Calcium | 57 | $634 |
| Metoprolol Succinate | 34 | $611 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $428 | $23,97125 claims |
| GSKAnoro Ellipta | $530 | $4,85511 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $99 | $4,67313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 287 rheumatology providers in Illinois.
Other rheumatology in Chicago
- Manish JainChicago$36.5M
- Theodore PincusChicago$524K
- Eric RudermanChicago$478K
- Anisha DuaChicago$284K
- Arthur MandelinChicago$270K
- Duncan MooreChicago$206K
- Joel BlockChicago$186K
- Timothy NiewoldChicago$165K
- Yvonne LeeChicago$157K
- Robert WoodrickChicago$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.